samarium has been researched along with Cancer of Prostate in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 6 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aktolun, C; Bodei, L; Delgado-Bolton, RC; Ezziddin, S; Gabriel, M; Giammarile, F; Handkiewicz-Junak, D; Poeppel, TD | 1 |
| Abbasi, A; Hassanzadeh, M; Sadikoglu, F | 1 |
| Becker, MD; Camphausen, K; Carrasquillo, JA; Chakraborty, M; Goeckeler, WF; Hodge, JW; Paik, CH; Schlom, J; Wansley, EK; Yu, S | 1 |
| Chaudhary, U; Turner, J | 1 |
| de Klerk, JM; Hoekstra, A; Lam, MG; van Rijk, PP; Zonnenberg, BA | 1 |
| Abrahamsen, J; Jakobsen, M; Jønler, M; Lund, L; Petersen, LJ | 1 |
| O'Sullivan, JM; Parker, CC; Vengalil, S | 1 |
| Morgans, AK; Smith, MR | 1 |
| Antczak, A; Baczyk, M; Gut, P; Hrab, M; Milecki, P; Pisarek, M | 1 |
| Douard, MC; George, B; Rain, JD | 1 |
| Cermáková, E; Dolezal, J; Vizd'a, J | 1 |
| Coleman, RE; Ell, PJ; Freeman, LM; Hoskin, PJ; Kotler, JA; Olivier, P; Quick, DP; Reid, RH; Sartor, O | 1 |
| Antoñanzas Villar, F; Carreras Coderch, L; Coya Viña, J; Echevarría Icaza, A; Martín Comín, J; Martínez Carderón, F; Nieto Martín-Bejarano, J; Sáenz Cusí, A; Serrano Bermúdez, G; Velasco Latrás, M | 1 |
| Bushnell, DL; Ell, PJ; Quick, DP; Reid, RH; Sartor, O | 1 |
| Dolezal, J; Odrazka, K; Vizda, J | 1 |
| Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA | 1 |
| Bushnell, D; Higano, CS; Quick, DP; Sartor, O | 1 |
| Ahonen, A; Hannelin, M; Heikkilä, J; Hiltunen, J; Jakobsson, M; Joensuu, H; Jurvelin, J; Kairemo, K; Kulmala, J; Kumpulainen, E | 1 |
| Addison, SJ; Appelbaum, F; Baker, M; Collins, C; Eary, JF; Ferency, S; Hartnett, S; Petersdorf, S; Stabin, M; Vernon, C | 1 |
| Appelbaum, FR; Bush, NE; Chapman, CR; Collins, C; Donaldson, G; Eary, JF; Gordon, EE; Livingston, RB; Petersdorf, S; Vernon, C | 1 |
| Coleman, RE | 1 |
| Cameron, PJ; Klemp, PF; Martindale, AA; Turner, JH | 1 |
| Dickie, GJ; Macfarlane, D | 1 |
| Lopez, JG; Manel, A; Perrin, P; Perrin-Fayolle, O; Ruffion, A; Valignat, C | 1 |
| DeWeese, TL; Ramakrishna, NR; Thurman, SA | 1 |
| Atefie, K; Köck, HH; Sinzinger, H; Weiss, K | 1 |
| Cutler, CS; Hoffman, T; Hu, F; Jurisson, SS; Sieckman, G; Volkert, WA | 1 |
| Curley, T; Larson, S; O'Moore, PV; Scher, HI; Tong, W; Yeh, S | 1 |
| Budd, RS; Martin, JJ; Sandeman, TF | 1 |
| Noujaim, AA; Tse, JW; Wiebe, LI | 1 |
6 review(s) available for samarium and Cancer of Prostate
| Article | Year |
|---|---|
Use of radionuclides in metastatic prostate cancer: pain relief and beyond.
Topics: Bone Neoplasms; Humans; Male; Men's Health; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radium; Rhenium; Samarium; Strontium | 2012 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid | 2012 |
[Metabolic radiotherapy: what role will it have in 2001?].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Analgesics, Opioid; Bone Neoplasms; Clinical Trials as Topic; Double-Blind Method; Forecasting; France; Hematologic Diseases; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Phosphorus Radioisotopes; Prospective Studies; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Rhenium; Samarium; Strontium; Strontium Radioisotopes; Treatment Outcome | 2002 |
How can we improve the treatment of bone metastases further?
Topics: Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Estrogen Antagonists; Female; Forecasting; Humans; Male; Multiple Myeloma; Osteolysis; Osteoporosis; Pain; Palliative Care; Prostatic Neoplasms; Quality of Life; Radioisotope Teletherapy; Randomized Controlled Trials as Topic; Samarium | 1998 |
Radiation therapy for the treatment of locally advanced and metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Brachytherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Gene Deletion; Gonadotropin-Releasing Hormone; Hemibody Irradiation; Hormone Antagonists; Humans; Male; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neutrons; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Proton Therapy; Radiation Tolerance; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, Conformal; Randomized Controlled Trials as Topic; Samarium; Strontium Radioisotopes; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; Humans; Male; Neoplasm Proteins; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rhenium; Samarium; Suramin | 1992 |
9 trial(s) available for samarium and Cancer of Prostate
| Article | Year |
|---|---|
A prospective randomized trial: a comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (m
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Organophosphorus Compounds; Pain Measurement; Prognosis; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Samarium | 2013 |
Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Diseases; Bone Neoplasms; Double-Blind Method; Drug Combinations; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Radioisotopes; Samarium | 2004 |
[Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases].
Topics: Adenocarcinoma; Analgesics, Non-Narcotic; Bone Neoplasms; Cost-Benefit Analysis; Drug Costs; Humans; Male; Models, Economic; Organometallic Compounds; Organophosphorus Compounds; Pain Measurement; Prostatic Neoplasms; Radioisotopes; Samarium; Treatment Outcome | 2005 |
Samarium-153-EDTMP in bone metastases.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Organotechnetium Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Samarium | 1994 |
Samarium-153-EDTMP biodistribution and dosimetry estimation.
Topics: Bone Neoplasms; Chelating Agents; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiotherapy Dosage; Samarium; Technetium Tc 99m Medronate; Tissue Distribution | 1993 |
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Hormones; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain Measurement; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiotherapy Dosage; Samarium | 1993 |
Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Topics: Bone Neoplasms; Breast Neoplasms; Disease Progression; Female; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage; Samarium; Tomography, Emission-Computed | 1999 |
Strontium and samarium therapy for bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Middle Aged; Prostatic Neoplasms; Radioisotopes; Retrospective Studies; Samarium; Strontium; Strontium Radioisotopes | 1999 |
Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
Topics: Animals; Bone Neoplasms; Dogs; Drug Screening Assays, Antitumor; Etidronic Acid; Growth Substances; Humans; Male; Neoplasm Proteins; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rhenium; Samarium; Suramin | 1992 |
16 other study(ies) available for samarium and Cancer of Prostate
| Article | Year |
|---|---|
EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
Topics: Bone Neoplasms; Humans; Male; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Quality of Life; Radioisotopes; Samarium; Strontium Radioisotopes | 2018 |
Effect of Au-197 nanoparticles along with Sm-153 radiopharmaceutical in prostate cancer from simulation method.
Topics: Chemoradiotherapy; Drug Combinations; Gold Colloid; Humans; Male; Metal Nanoparticles; Models, Biological; Monte Carlo Method; Prostate; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Samarium | 2019 |
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Separation; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Organometallic Compounds; Organophosphorus Compounds; Phenotype; Prostatic Neoplasms; Radioisotopes; Samarium; T-Lymphocytes, Cytotoxic; Treatment Outcome | 2008 |
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Basidiomycota; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Leuprolide; Lumbar Vertebrae; Male; Nitriles; Phytotherapy; Plant Extracts; Polysaccharides; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Remission Induction; Samarium; Self Medication; Spinal Neoplasms; Tosyl Compounds | 2009 |
Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Topics: Adult; Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Etidronic Acid; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radiation Injuries; Radioisotopes; Rhenium; Safety; Samarium; Strontium; Strontium Radioisotopes | 2009 |
Samarium-153 treatment of bone pain in patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Male; Pain; Pain Measurement; Palliative Care; Prostatic Neoplasms; Radioisotopes; Samarium | 2010 |
[Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain, Intractable; Palliative Care; Pancytopenia; Prostatic Neoplasms; Radiopharmaceuticals; Samarium | 2003 |
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Palliative Care; Prospective Studies; Prostatic Neoplasms; Safety; Samarium | 2007 |
Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Radionuclide Imaging; Samarium; Treatment Outcome | 2007 |
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Metabolic Clearance Rate; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Samarium; Zoledronic Acid | 2008 |
Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Bone Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Samarium; Survival Rate | 2008 |
Successful use of Samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Bone Neoplasms; Disseminated Intravascular Coagulation; Gingival Hemorrhage; Hematoma; Hemostatic Techniques; Humans; Injections, Intravenous; Male; Middle Aged; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Samarium | 2000 |
Complete scintigraphic lesion regression after single 153Sm-EDTMP therapy in prostate cancer.
Topics: Adenocarcinoma; Bone Neoplasms; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Palliative Care; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Remission Induction; Samarium | 2001 |
Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).
Topics: Animals; Bombesin; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Metabolic Clearance Rate; Metals, Rare Earth; Mice; Peptide Fragments; Promethium; Prostatic Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Samarium; Sensitivity and Specificity; Tissue Distribution | 2002 |
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
Topics: Aged; Aged, 80 and over; Bone Marrow; Bone Neoplasms; Carcinoma; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Palliative Care; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiotherapy Dosage; Remission Induction; Samarium; Survival Rate; Thrombocytopenia | 1992 |
Comparative studies of radiotracer citrates in oncological models--2. 153Sm-citrate and 67Ga-citrate.
Topics: Animals; Citrates; Colloids; Gallium Radioisotopes; Humans; Liver; Male; Melanoma; Metabolic Clearance Rate; Mice; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Rats; Rats, Inbred Strains; Samarium; Tissue Distribution; Tumor Cells, Cultured | 1989 |